Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc.'s MRNA, -2.76% stock has tumbled 63% from last summer's record high, but the recent resurgence of COVID-19 cases in Europe and Asia is already rallying shares.

Moderna's stock, down 60% since the summer's delta wave, is rising again as COVID-19 cases increase

Investors in Moderna (MRNA) stock will want to keep an eye on the company when Thursday rolls around as it prepares to discuss vaccines. The post Dear MRNA Stock Fans, Mark Your Calendars for This Potential Moderna Catalyst on March 24 appeared first on InvestorPlace.

Dear MRNA Stock Fans, Mark Your Calendars for This Potential Moderna Catalyst on March 24

Netflix

Don't be too quick to abandon these companies.

2 Top Nasdaq Stocks to Buy on the Dip

Alnylam Pharmaceuticals

Doximity

These former stock market darlings could recoup some of the heavy losses they recently suffered.

3 Healthcare Stocks That Could Rise 28% or More, According to Wall Street

CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss Federal Government for seven million doses of Moderna's COVID-19 booster vaccine for anticipated delivery in 2023 and an additional option of seven million doses for delivery in 2023 and 2024. These doses are in addition to the seven million doses of Moderna's booster vaccine that are scheduled for supply to Switzerland in the second half of 2022, which the Government exercised its option to purchase in December 2021.

Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine

AbbVie

Merck

These health care stocks could be worth a look as the stock market moves sideways.

3 Top Health Care Stocks To Watch Right Now

Pfizer

An increase in Covid-19 cases in some European countries tied to an Omicron sub-variant has raised concerns about another surge to come.

What Moderna and Pfizer's Vaccine Moves Say About Covid's Next Phase

Earlier this week, Pfizer asked the FDA to authorize an extra booster for those age 65 and up.

Moderna Asks FDA to Authorize Second COVID Booster for All Adults

Moderna Inc has applied to the US Food and Drug Administration (FDA) for authorisation of a second COVID-19 booster shot for adults 18 and older. This would be Moderna's second booster shot for people 18 and up, if approved.

Moderna requests emergency approval for a second Covid booster for all adults

A new set of patent lawsuits over the technology behind the messenger RNA-based Covid-19 vaccines increases risks for Moderna stock, but could take years to play out.

New Patent Lawsuit Adds to Litigation Worries for Moderna Stock

Moderna's request is broader than one submitted by Pfizer and BioNTech earlier this week.

Moderna Seeks FDA Clearance for Second Covid-19 Booster Shot in All Adults

Moderna's request comes in the same week that Pfizer asked the FDA to approve a second vaccine booster shot for people aged 65 and over.

Moderna is seeking FDA approval for a 4th COVID-19 vaccine shot for those aged 18 and above

Moderna's request comes two days after Pfizer asked the FDA to approve a second booster shot for seniors.

Moderna Asks FDA To Authorize 4th Covid Vaccine Dose For All Adults

WASHINGTON — Drug maker Moderna MRNA, -0.65% asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.

Moderna seeks FDA approval for fourth dose of COVID vaccine for all adults

CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines. The request to include adults over 18 years of age was made to provide flexibility for the U.S. Centers for Disease Control and Prevention (CDC) and healthcare providers to determine the appropriate use of an additional booster dose of mRNA-1273, including for those at higher risk of COVID-19 due to age or comorbidities.

Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.

A resurgence in COVID-19 cases in China and Europe is the key driver behind Moderna's rebound.

Why Moderna Stock Is Soaring This Week

Stephane Bancel cashed out stock options through the 10b5-1 plan which allows executives to sell a predetermined number of shares at regular intervals to avoid the possibility of insider trading.

Moderna CEO sold more than $400 million in company stock during pandemic

Moderna, Inc. (MRNA) Management Presents at Oppenheimer's 32nd Annual Healthcare Brokers Conference [Transcript]

Lucid Group

PayPal

The odds are favoring a new bullish cycle for the market. That's likely to help these three Nasdaq 100 stocks make a comeback.

3 Beaten-Down Nasdaq 100 Stocks to Buy Before They Rebound

Health Canada has approved Moderna Inc's (NASDAQ: MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the.

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.

Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?

Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of Moderna's mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 50 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 to11 years.

Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)

Moderna CEO Stephane Bancel has sold more than 2.8 million shares since January 2020 at a total value of more than $408 million.

Moderna CEO Stephane Bancel has sold more than $400 million of company stock during the pandemic

Alnylam Pharmaceuticals Inc said on Thursday it has separately filed lawsuits against Pfizer Inc and Moderna Inc, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.

Alnylam files patent infringement lawsuits against Pfizer, Moderna

Moderna Inc. MRNA, -1.30% said Wednesday the Japanese government has ordered an additional 70 million doses of its COVID-19 booster vaccine or an updated booster vaccine candidate, if one wins authorization. The doses are expected to be delivered in the second half of 2022.

News for Moderna Stock (MRNA)